menu
    • menu
    [{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MTX652","moa":"USP-30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MTX652","moa":"USP-30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"PS-002","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purespring Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"5","companyTruncated":"Purespring Therapeutics \/ Sofinnova Partners"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PS-002","moa":"CFI","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purespring Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Purespring Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Purespring Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed

                            Purespring Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Purespring Wins EMA Orphan Drug Status for PS-002 in IgA Nephropathy

                            Details : PS-002 is a Purespring’s lead cell and gene therapy programme, currently being investigated in patients with IgA nephropathy (IgAN).

                            Product Name : PS-002

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 28, 2025

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Purespring Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed

                            Purespring Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Sofinnova Partners

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Purespring Therapeutics Raises $105M to Transform Kidney Disease Treatment

                            Details : The proceeds will be used to support Purespring’s pipeline including the initiation of a Phase I/II clinical trial of PS-002 for IgAN, a chronic kidney disease primarily affecting young adults.

                            Product Name : PS-002

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Sofinnova Partners

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mission Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed

                            Mission Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTX652

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mission Therapeutics Announces US FDA Approval to Initiate Phase II Clinical Trial of its Lead Asset MTX652 in...

                            Details : MTX652 is a potent and selective compound designed to improve mitochondrial quality and function by enhancing mitophagy through inhibition of USP30 enzyme. It is being evaluated for the treatment of acute kidney injury (AKI) following cardiac surgery.

                            Product Name : MTX652

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 14, 2023

                            Lead Product(s) : MTX652

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mission Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed

                            Mission Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTX652

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mission Therapeutics Authorised to Initiate First Clinical Trial for Lead DUB Program, MTX652, in Kidney Disea...

                            Details : Mission has developed MTX652 to inhibit USP30 with the aim to enable appropriate degradation of dysfunctional mitochondria to preserve and improve cellular health. Mission is also investigating the potential of USP30 inhibitors to treat these diseases.

                            Product Name : MTX652

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : MTX652

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth